Mr. Speaker, I am very supportive of the bill. I did chair a subcommittee of the health committee on controlled drugs and substances, where we initially set up the schedules on precursors, designer drugs and a few other things.
There were a couple of questions and maybe the member can assist. The coordinating amendment in the bill seems to make a reference to subsection 19(8) and the reference in the member's bill is to subsection 1(9) of schedule III, not schedule I. I do not have the bills before me, but I wonder if the member could please explain what the difference would be if his bill is overridden by the government bill that is already in process.
Finally, since he has done all the work now, I wonder if the member has any comments on whether or not the process that we have to go through to amend the schedules to the Controlled Drugs and Substances Act seems to be fairly onerous and may not be able to respond to the velocity of changes in terms of the advancement of drug science.